Discover CME, tools, and guideline-focused education to improve your knowledge - and patient outcomes.
Insights and Updates: New Data on Next-Generation Retinal Treatments
Durga Borkar, MD, MMCi
Veeral Sheth, MD, MBA, FASRS, FACS
Why CELMoDs Matter in Myeloma
Sagar Lonial, MD, FACP
Molecular Magic: Decoding the Unique Mechanism of CELMoDs
Noopur Raje, MD
Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma Activity
Joshua Richter, MD
Data Dive: Clinical Evidence Behind CELMoDs
Real-World Ready: Practical Tips for Community Oncologists
Safety First: Navigating CELMoD-Associated Toxicities
Chairperson’s Perspective: Optimizing Perioperative Therapy in Early-Stage NSCLC: A Multidisciplinary Approach
Heather Wakelee, MD, FASCO
Precision Targeting: Matching CELMoDs to the Right Patient With Myeloma
Case Application: Unlocking Relapsed/Refractory Myeloma With CELMoDs
Chairperson Perspective: Acromegaly Care: Individualized Diagnosis and Management Strategies
Maria Fleseriu, MD, FACE
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
Paolo A. Ascierto, MD
Hussein Tawbi, MD, PhD
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
John M. Kirkwood, MD
Sapna Patel, MD
Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma
Next-Generation Innovations: The Future of CELMoDs in Myeloma
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
Innovations in Oncology Learning Center: From Guidelines to Practice: Melanoma
Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
Community Clinic: Translating Data Into Action ─ Practical Strategies for Optimizing First-Line RCC Management
Robert J. Motzer, MD
Elizabeth R. Plimack, MD, MS, FASCO
Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy
Kevin Kalinsky MD, MS
Komal Jhaveri, MD, FACP
HER2 in Bladder Cancer: Breaking Through the Molecular Frontier
Vadim S. Koshkin, MD
Advancing Myasthenia Gravis (MG) Treatment Through Guideline Updates and Emerging Therapies
October 30, 2025
San Francisco, California
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.